CRISPR-based gene therapy cleared for beta-thalassemia

The FDA has authorized expanded indications for exagamglogene autotemcel (Casgevy), the first CRISPR/Cas9 genome editing therapy approved in the U.S. for sickle cell disease, to include the treatment of transfusion-dependent beta-thalassemia in patients 12 years and older.